Aller au contenu principal
2026 article

GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been associated with systemic anti‐inflammatory effects in addition to weight loss. Their effect on idiopathic subglottic stenosis (iSGS) has not been evaluated. This study aimed to characterize the effect of GLP‐1RAs on surgery‐free interval (SFI) in iSGS. Study Design Retrospective cohort study. Setting Single‐institution academic center. Methods Two hundred and twenty‐three iSGS patients were reviewed for GLP‐1RA usage. SFI, and secondary measures of weight loss, body mass index (BMI), and Cotton‐Myer grade before and after starting GLP‐1RAs were analyzed. Patients were excluded if GLP‐1RAs were begun prior to establishing SFI, or if serial intralesional steroid injection or endoscopic or open cricotracheal resection were performed. Statistical comparisons for SFI and weight loss were performed with paired t tests, univariate, and multiple linear regression, and a generalized linear mixed‐effects model was used to compare Cotton‐Myer grades, with a threshold for significance of α = .05. Results Thirty‐two patients (14%) were taking GLP‐1RAs, with 14 meeting the inclusion criteria. SFI increased by a mean of 10.7 months, or 68.5% ( P = .001). Patients lost 39 pounds on average, with a mean BMI decrement of 6.8 points ( P < .001). There was no appreciable correlation between weight loss, initial BMI, and SFI on multiple linear regression ( P = .92, adjusted R 2 = −0.16) or univariate linear regression between SFI and weight loss ( P = .98, R 2 < 0.001) or BMI ( P = .72, R 2 = 0.01). There was no difference in Cotton‐Myer grade at the time of surgery between patients before and after starting therapy ( P = .44). Conclusion GLP‐1RA therapy increases SFI in iSGS independent of initial BMI or weight loss. Level of Evidence IV.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis
Date Crossref
06/07/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Tracheal and airway disordersDysphagia Assessment and ManagementObstructive Sleep Apnea Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.